Live
- Gold prices likely to further come down with no near-term positive triggers
- Tough decision, but it's the right one: Southee on Test retirement
- After caste census, Dalits, tribals, poor will recognise their true strength: Rahul Gandhi
- Who was Birsa Munda, whose 'Ulgulan' declared the end of British rule in Jharkhand?
- Logistic firm Delhivery’s profit tanks over 80 pc in April-Sep period
- Five selected as Indian Rhodes Scholars for 2025
- Raj Thackeray releases MNS election Manifesto with a ‘key’ to implementing it
- COP29: 3 methodologies approved for issuing high-integrity carbon credits
- MP: Celebrations of Birsa Munda's birth anniversary begin in presence of Guv, CM in Shahdol
- NGT seeks details of waste to energy plants not complying with norms
Jardiance gets CDSCO nod
Highlights
Central Drugs Standard Control Organisation (CDSCO) has approved Jardiance (empagliflozin) 10mg tablets to reduce the risk of sustained decline in...
Central Drugs Standard Control Organisation (CDSCO) has approved Jardiance (empagliflozin) 10mg tablets to reduce the risk of sustained decline in eGFR (only for patients with eGFR 30-90 ml/min/1.73m2), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
This indication approval allows the nephrologists and cardiologists to use Jardiance 10mg tablets for the treatment of CKD. “Chronic kidney disease is an important health issue,” said Gagandeep Singh Bedi, Managing Director, Boehringer Ingelheim India.
Next Story
ADVERTISEMENT
